The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
300 jobs Number of planned job creations
Announcement Date
28 January 2022
Employment effect (start)
28 January 2022
Foreseen end date
1 February 2026
Description
American pharmaceutical multinational Eli Lilly is to create 300 permanent jobs at a new manufacturing plant in Limerick. It is part of an investment of €400 million. The new plant will expand the company’s capacity to make innovative new medicines that can help treat some of the world’s most serious illnesses. The plant will be fully operational by early 2026 and the recruitment will start immediately. New roles will include engineers, scientists, and operations personnel.
Currently, Eli Lilly employs over 2,300 people at two plants in Cork.
Eurofound (2022), Eli Lilly, Business expansion in Ireland, factsheet number 106284, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/106284.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
